NOVEL DRUG DELIVERY SYSTEMS FOR EFFECTIVE DELIVERY OF DRUGS IN THE MANAGEMENT OF RHEUMATOID ARTHRITIS

Chronic joint inflammation is a hallmark of the systemic inflammatory illness known as rheumatoid arthritis (RA), which eventually causes severe disability and early death. RA may impact any joint in the body. However, it mostly impacts the wrist and knee joints’ proximal interphalangeal, metacarpophalangeal and metatarsophalangeal joints. Around 1% of people worldwide are affected by it and women are 2-3 times more likely to be affected than males. Preclinical RA, genetic influences and environmental influences all have a role in the etiology of the illness. Since there is no recognized therapy for RA, achieving the lowest disease activity and, if possible, recovery remains the key goals of care. This review summarizes the research on the many RA therapy options, their mechanisms of action, side effects and novel drug delivery systems currently being used for non-steroidal anti-inflammatory drugs (NSAIDs). These delivery methods are discovered to be non-toxic, physiologically selective, compatible with cells and tissues and safe even at larger doses. The current study compares and contrasts numerous unique drug delivery methods that have been investigated for using anti-rheumatic medications, as well as the benefits of using these novel methods over traditional drug delivery methods. This will reduce the need for high doses and frequent dosing as well as the toxic side effects of the drugs, making medications safer for patients. To make these potential medication delivery methods commercially marketable, additional in-depth studies are urgently required.